BACKGROUND: Highly active antiretroviral therapies (HAART) in HIV-infected patients are often associated with lipodystrophy syndrome and metabolic disorders. Atherogenic lipid profile could expose these patients to atheromatous cardiovascular disease. We describe carotid artery intima-media thickness (IMT), a surrogate marker of atherosclerosis, according to HIV status, antiretroviral treatment, lipodystrophy and conventional cardiovascular risk factors. METHOD: In a multicenter prospective cohort study we have surveyed HIV-infected subjects with a carotid IMT measurement by B-mode ultrasonography. We collected information on lipodystrophy clinical manifestations, age, gender, body mass index (BMI), smoking habits, alcohol intake, systolic blood pressure, HIV transmission category, AIDS stage, type and duration of HAART, CD4+ cell count, plasma HIV-1 RNA, glucose, insulin, total cholesterol and homocysteine. RESULTS: Four hundred and twenty-three HIV-infected patients were studied. The median carotid IMT measurement was 0.54 mm (range: 0.50-0.60). Lipodystrophy syndrome was diagnosed in 161 HIV-infected patients (38.1%). In univariate linear regression, IMT was significantly higher (P<0.05) with older age, male gender, higher body mass index, higher waist-to-hip ratio, increased systolic blood pressure, total cholesterol, glucose disorders and homocysteine, regular smoking and alcohol consumption, lipodystrophy and HAART. In a multivariate analysis, the effect of lipodystrophy and HAART disappeared after adjustment for other cardiovascular risk factors. CONCLUSIONS: It was concluded that only conventional cardiovascular risk factors are independently associated with increased IMT in HIV-infected patients.
BACKGROUND: Highly active antiretroviral therapies (HAART) in HIV-infectedpatients are often associated with lipodystrophy syndrome and metabolic disorders. Atherogenic lipid profile could expose these patients to atheromatous cardiovascular disease. We describe carotid artery intima-media thickness (IMT), a surrogate marker of atherosclerosis, according to HIV status, antiretroviral treatment, lipodystrophy and conventional cardiovascular risk factors. METHOD: In a multicenter prospective cohort study we have surveyed HIV-infected subjects with a carotid IMT measurement by B-mode ultrasonography. We collected information on lipodystrophy clinical manifestations, age, gender, body mass index (BMI), smoking habits, alcohol intake, systolic blood pressure, HIV transmission category, AIDS stage, type and duration of HAART, CD4+ cell count, plasma HIV-1 RNA, glucose, insulin, total cholesterol and homocysteine. RESULTS: Four hundred and twenty-three HIV-infectedpatients were studied. The median carotid IMT measurement was 0.54 mm (range: 0.50-0.60). Lipodystrophy syndrome was diagnosed in 161 HIV-infectedpatients (38.1%). In univariate linear regression, IMT was significantly higher (P<0.05) with older age, male gender, higher body mass index, higher waist-to-hip ratio, increased systolic blood pressure, total cholesterol, glucose disorders and homocysteine, regular smoking and alcohol consumption, lipodystrophy and HAART. In a multivariate analysis, the effect of lipodystrophy and HAART disappeared after adjustment for other cardiovascular risk factors. CONCLUSIONS: It was concluded that only conventional cardiovascular risk factors are independently associated with increased IMT in HIV-infectedpatients.
Authors: Eric C Seaberg; Lorie Benning; A Richey Sharrett; Jason M Lazar; Howard N Hodis; Wendy J Mack; Mark J Siedner; John P Phair; Lawrence A Kingsley; Robert C Kaplan Journal: Stroke Date: 2010-08-26 Impact factor: 7.914
Authors: Lance T Vernon; Denise C Babineau; Catherine A Demko; Michael M Lederman; Xuelei Wang; Zahra Toossi; Aaron Weinberg; Benigno Rodriguez Journal: AIDS Res Hum Retroviruses Date: 2011-05-09 Impact factor: 2.205
Authors: Alexandra Mangili; Raabia Ahmad; Robert L Wolfert; Jeffrey Kuvin; Joseph F Polak; Richard H Karas; Christine A Wanke Journal: Clin Infect Dis Date: 2013-12-11 Impact factor: 9.079
Authors: Judith S Currier; Michelle A Kendall; Robert Zackin; W Keith Henry; Beverly Alston-Smith; Francesca J Torriani; Jeff Schouten; Keith Mickelberg; Yanjie Li; Howard N Hodis Journal: AIDS Date: 2005-06-10 Impact factor: 4.177
Authors: Kathleen V Fitch; Sara E Looby; Alison Rope; Peace Eneh; Linda Hemphill; Hang Lee; Steven K Grinspoon Journal: AIDS Date: 2013-01-02 Impact factor: 4.177
Authors: K Petoumenos; S Worm; P Reiss; S de Wit; A d'Arminio Monforte; C Sabin; N Friis-Møller; R Weber; P Mercie; C Pradier; W El-Sadr; O Kirk; J Lundgren; Mg Law Journal: HIV Med Date: 2011-01-20 Impact factor: 3.180